These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
343 related articles for article (PubMed ID: 28331132)
1. Orbital MALT Lymphoma after Autologous Stem Cell Transplantation for Follicular Lymphoma as Relapse of Diffuse Large B-Cell Lymphoma. Matsuo T; Tanaka T; Fujii N J Clin Exp Hematop; 2017; 56(3):170-175. PubMed ID: 28331132 [TBL] [Abstract][Full Text] [Related]
2. Sequential development of multifocal recurrent non-Hodgkin's lymphoma of mucosa-associated lymphoid tissue and diffuse large B-Cell lymphoma in a single patient: A case report. Yang X; Min X; He W Medicine (Baltimore); 2018 May; 97(21):e10845. PubMed ID: 29794780 [TBL] [Abstract][Full Text] [Related]
3. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386 [TBL] [Abstract][Full Text] [Related]
4. Orbital MALT lymphoma, abdominal hodgkin lymphoma, and systemic diffuse large B-cell lymphoma develop sequentially in one patient. Matsuo T; Ichimura K; Shinagawa K J Clin Exp Hematop; 2012; 52(1):41-9. PubMed ID: 22706530 [TBL] [Abstract][Full Text] [Related]
5. A salvage chemotherapy of R-P-IMVP16/CBDCA consisting of rituximab, methylprednisolone, ifosfamide, methotrexate, etoposide, and carboplatin for patients with diffuse large B cell lymphoma who had previously received R-CHOP therapy as first-line chemotherapy. Matsumoto T; Hara T; Shibata Y; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Kanemura N; Goto N; Kito Y; Kasahara S; Yamada T; Sawada M; Miyazaki T; Takami T; Takeuchi T; Moriwaki H; Tsurumi H Hematol Oncol; 2017 Sep; 35(3):288-295. PubMed ID: 26999778 [TBL] [Abstract][Full Text] [Related]
6. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]
7. Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma. Derenzini E; Musuraca G; Fanti S; Stefoni V; Tani M; Alinari L; Venturini F; Gandolfi L; Baccarani M; Zinzani PL Cancer; 2008 Nov; 113(9):2496-503. PubMed ID: 18833583 [TBL] [Abstract][Full Text] [Related]
8. Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation. Gkotzamanidou M; Papadimitriou CA Crit Rev Oncol Hematol; 2014 Feb; 89(2):248-61. PubMed ID: 24075060 [TBL] [Abstract][Full Text] [Related]
9. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy. Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567 [TBL] [Abstract][Full Text] [Related]
10. [Follicular lymphoma: first - line selection criteria of treatment]. Nesterova ES; Kravchenko SK; Kovrigina AM; Gemdzhian EG; Plastinina LV; Babaeva FE; Obukhova TN; Magomedova AU; Gaponova TV; Kremenetskaya AM; Vorobyev AI Ter Arkh; 2019 Aug; 91(8):75-83. PubMed ID: 32598757 [TBL] [Abstract][Full Text] [Related]
11. Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study. van Imhoff GW; McMillan A; Matasar MJ; Radford J; Ardeshna KM; Kuliczkowski K; Kim W; Hong X; Goerloev JS; Davies A; Barrigón MDC; Ogura M; Leppä S; Fennessy M; Liao Q; van der Holt B; Lisby S; Hagenbeek A J Clin Oncol; 2017 Feb; 35(5):544-551. PubMed ID: 28029326 [TBL] [Abstract][Full Text] [Related]
12. Treatment of relapsed non-Hodgkin's lymphoma after BEAM chemotherapy and autologous transplantation by BU/CY chemotherapy and salvage transplantation. Fetscher S; Lübbert M; Kanz L; Behringer D; Finke J; Mertelsmann R; Lange W Bone Marrow Transplant; 1997 Mar; 19(5):527-8. PubMed ID: 9052926 [TBL] [Abstract][Full Text] [Related]
13. Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial. Fayad L; Ansell SM; Advani R; Coiffier B; Stuart R; Bartlett NL; Forero-Torres A; Kuliczkowski K; Belada D; Ng E; Drachman JG Leuk Lymphoma; 2015; 56(9):2569-78. PubMed ID: 25651427 [TBL] [Abstract][Full Text] [Related]
14. Primary radiation therapy in patients with localized orbital marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT Lymphoma). Son SH; Choi BO; Kim GW; Yang SW; Hong YS; Choi IB; Kim YS Int J Radiat Oncol Biol Phys; 2010 May; 77(1):86-91. PubMed ID: 19632068 [TBL] [Abstract][Full Text] [Related]
17. Is there any role for transplantation in the rituximab era for diffuse large B-cell lymphoma? Gisselbrecht C Hematology Am Soc Hematol Educ Program; 2012; 2012():410-6. PubMed ID: 23233612 [TBL] [Abstract][Full Text] [Related]
18. Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients. Caimi PF; William BM; Silva Rondon CH; Fu P; Cooper BW; Campagnaro EL; Gerson SL; Reese-Koc J; Fox R; Creger RJ; de Lima M; Lazarus HM Biol Blood Marrow Transplant; 2015 Nov; 21(11):1926-31. PubMed ID: 26087475 [TBL] [Abstract][Full Text] [Related]
19. Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma. Feldman T; Mato AR; Chow KF; Protomastro EA; Yannotti KM; Bhattacharyya P; Yang X; Donato ML; Rowley SD; Carini C; Valentinetti M; Smith J; Gadaleta G; Bejot C; Stives S; Timberg M; Kdiry S; Pecora AL; Beaven AW; Goy A Br J Haematol; 2014 Jul; 166(1):77-83. PubMed ID: 24661044 [TBL] [Abstract][Full Text] [Related]
20. Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography. Pinnix CC; Dabaja B; Ahmed MA; Chuang HH; Costelloe C; Wogan CF; Reed V; Romaguera JE; Neelapu S; Oki Y; Rodriguez MA; Fayad L; Hagemeister FB; Nastoupil L; Turturro F; Fowler N; Fanale MA; Nieto Y; Khouri IF; Ahmed S; Medeiros LJ; Davis RE; Westin J Int J Radiat Oncol Biol Phys; 2015 May; 92(1):113-21. PubMed ID: 25863759 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]